EPGNY

Epigenomics AG [EPGNY] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

EPGNY Stock Summary

In the News

EPGNY Financial details

Company Rating
-
Market Cap
0
Income
-7.31M
Revenue
567K
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
33
Optionable
No
Shortable
Yes
Earnings
-
P/E
-5.13
Forward P/E
-
PEG
0.62
P/S
-
P/B
2.05
P/C
-
P/FCF
-
Quick Ratio
3.62
Current Ratio
3.88
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.44
EPS next Y
-
EPS next Q
-
EPS this Y
-89.11%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-41.47%
Revenue last 5Y
27.18%
Revenue Q/Q
15.08%
EPS Q/Q
20%
-
-
-
-
SMA20
-39.95%
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-29%
ROE
-34%
ROC
-0.37%
Gross Margin
76%
Oper. Margin
-1412%
Profit Margin
-1442%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
2.005-14.37
52W High
-82.93%
52W Low
+19.5%
RSI
47.75
Rel Volume
-
Avg Volume
9
Volume
Perf Week
0%
Perf Month
0%
Perf Quarter
-
Perf Half Y
0%
-
-
-
-
Beta
1.18699
-
-
Volatility
0%, 1.79%
Prev Close
0%
Price
2.39
Change
0%

Something similar

Top by Market Cap
LLY.SW
1YD.DE
0YXG.L
VFINX
M&M.NS
Same Sector
CDXI
6622.HK
GHSI
AALR3.SA
LFLY
Check Those
OSW
NPK.TO
OLB
DRH-PA
8250.SR
Similar Market Cap
MDC
NQWFX
0N9Z.L
YALA
PRR.CN

Company Profile

Healthcare Medical - Diagnostics & Research

Epigenomics AG, a molecular diagnostics company, focuses on liquid biopsy for the early detection of cancer. Its lead product is Epi proColon, a blood-based test for the early detection of colorectal cancer in the United States, Europe, and China. The company's products also include hepatocellular carcinoma blood test; Epi proColon, a liquid biopsy test for detection of colorectal cancer; and Epi BiSKit, a pre-analytical tool, which provides a set of reagents for the preparation of bisulfite-converted DNA. Its research and development activities identify suitable biomarkers in human tissue and developing and patenting the corresponding in vitro diagnostic blood tests. Epigenomics AG was founded in 1998 and is headquartered in Berlin, Germany.